BeOne Medicines (BEIGF) Total Liabilities (2015 - 2026)

BeOne Medicines (BEIGF) has 12 years of Total Liabilities data on file, last reported at $3.8 billion in Q1 2026.

• Total Liabilities for Q1 2026 came in at $3.8 billion, up 61.96% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.8 billion (up 61.96% YoY), and the FY2025 annual result was $3.8 billion, up 47.85% from the prior year.
• Total Liabilities retreated to $3.8 billion in Q1 2026 per BEIGF's latest filing, from $3.8 billion in the prior quarter.
• Over five years, Total Liabilities peaked at $3.8 billion in Q4 2025 and troughed at $1.1 billion in Q4 2022.
• A 5-year average of $2.4 billion and a median of $2.3 billion in 2024 frame the typical range for Total Liabilities.
• The sharpest annual moves came in 2022 and 2023: Total Liabilities slumped 54.31% in 2022, then surged 106.59% in 2023.
• A 5-year view of Total Liabilities shows it stood at $1.1 billion in 2022, then soared by 106.59% to $2.3 billion in 2023, then increased by 14.14% to $2.6 billion in 2024, then surged by 47.85% to $3.8 billion in 2025, then slipped by 0.89% to $3.8 billion in 2026.
• Business Quant data shows BEIGF's Total Liabilities at $3.8 billion in Q1 2026, $3.8 billion in Q4 2025, and $3.5 billion in Q3 2025.